| Inverness Medical extends notes exchange (AP) Inverness Medical Innovations extended its offer Monday to exchange $100 million in 7.875 percent senior notes due 2016. us.rd.yahoo.com |
Genzyme Catches Eye of Others Sanofi-Aventis may not be the only big drug maker interested in Genzyme, after news of Sanofi's interest in the U.S. biotech company became public. online.wsj.com |
Theragenics Corporation Q2 2010 Earnings Call Transcript Theragenics Corporation (TGX)Q2 2010 Earnings Call TranscriptAugust 10, 2010 11:00 am ETComplete Story » seekingalpha.com |
Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes [PR Newswire] - Spherix Incorporated , an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 3 study of D-tagatose as a monotherapy in Type 2 diabetes showed a statistically significant reduction in HbA1c levels of 0.4% at 10 months in relatively healthy people with diabetes *. Â The reduction was even more pronounced among PP patients treated in the U.S., and the reduction in HbA1c generally increased over the 10 months patients were treated . us.rd.yahoo.com |
Bristol-Myers Profit Slips Bristol-Myers posted a small decline in third-quarter profit, though fewer shares outstanding and lower costs translated into an increase in per-share earnings. online.wsj.com |